Diligence memo · auto-generated · as of July 2, 2026
Vbi Vaccines Inc.
Vbi Vaccines Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Vbi Vaccines Inc. operates in Biotechnology, based in CAMBRIDGE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Vbi Vaccines Inc. has raised $54M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $36M on 2014-07-25.
Most recent recorded round closed around 2015-08-13.
Valuation (modeled)modeled
Provath models Vbi Vaccines Inc. at approximately $249M (range $13M–$960M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.35× the median modeled value of Series B Biotechnology companies in 2013–2015 (77 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 6 months.
Last raise 10.9 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.8× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 83% of Biotechnology peers (4293 compared).
Modeled value ranks above 75% of those peers.
Closest niche peers: BioAtla,LLC, Scholar Rock LLC, Oligasis, LLC, Alector LLC, Gelesis Inc.
Peoplefiled
19 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.